Exploring the Anti-ageing Effects of Metformin in COPD

Summary

Prospective, multicentre, double-blind, placebo-controlled, randomised, prospective clinical trial comparing the effect of metformin 850 mg twice daily with placebo in COPD patients with evidence of emphysema (by CT scan or reduced DLCO) who are known to have a rapid decrease in FEV1. Main objective: To compare the change in FEV1 at 3 years follow-up in patients receiving metformin versus placebo. Participants will take metformin (850mg) or placebo twice daily for 3 years.

Timeline

Start

2025-09-01

Primary completion

2029-05-01

Completion

2029-09-01

Drugs

Indications